A novel mammalian expression system derived from components coordinating nicotine degradation in *arthrobacter nicotinovorans* pAO1

Laetitia Malphettes¹, Cornelia C. Weber², Marie Daoud El-Baba³, Ronald G. Schoenmakers¹,⁴, Dominique Aubel³, Wilfried Weber¹ and Martin Fussenegger¹,*

¹Institute for Chemical and Bio-Engineering (ICB), Swiss Federal Institute of Technology, ETH Hoenggerberg, HCI F115, Wolfgang-Pauli-Strasse 10, CH-8093 Zurich, Switzerland, ²Novartis Pharma AG, CH-4002 Basel, Switzerland, ³Département Génie Biologique, Institut Universitaire de Technologie, IUTA, 43 Boulevard du 11 Novembre 1918, F-69622 Villeurbanne Cedex, France and ⁴Integrative Bioscience Institute, Swiss Federal Institute of Technology Lausanne, CH-1015 Lausanne, Switzerland

Received March 29, 2005; Revised and Accepted June 20, 2005

ABSTRACT

We describe the design and detailed characterization of 6-hydroxy-nicotine (6HNic)-adjustable transgene expression (NICE) systems engineered for lentiviral transduction and in vivo modulation of angiogenic responses. *Arthrobacter nicotinovorans* pAO1 encodes a unique catabolic machinery on its plasmid pAO1, which enables this Gram-positive soil bacterium to use the tobacco alkaloid nicotine as the exclusive carbon source. The 6HNic-responsive repressor-operator (HdnoR-ONIC) interaction, controlling 6HNic oxidase production in *A. nicotinovorans* pAO1, was engineered for generic 6HNic-adjustable transgene expression in mammalian cells. HdnoR fused to different transactivation domains retained its ONIC-binding capacity in mammalian cells and reversibly adjusted transgene transcription from chimeric ONIC-containing promoters (PNIC; ONIC fused to a minimal eukaryotic promoter [Pmin] in a 6HNic-responsive manner. The combination of transactivators containing various transactivation domains with promoters differing in the number of operator modules as well as in their relative inter-ONIC and/or ONIC-Pmin spacing revealed steric constraints influencing overall NICE regulation performance in mammalian cells. Mice implanted with microencapsulated cells engineered for NICE-controlled expression of the human glycoprotein secreted placental alkaline phosphatase (SEAP) showed high SEAP serum levels in the absence of regulating 6HNic. 6HNic was unable to modulate SEAP expression, suggesting that this nicotine derivative exhibits control-incompatible pharmacokinetics in mice. However, chicken embryos transduced with HIV-1-derived self-inactivating lentiviral particles transgenic for NICE-adjustable expression of the human vascular endothelial growth factor 121 (VEGF121) showed graded 6HNic response following administration of different 6HNic concentrations. Owing to the clinically inert and highly water-soluble compound 6HNic, NICE-adjustable transgene control systems may become a welcome alternative to available drug-responsive homologs in basic research, therapeutic cell engineering and biopharmaceutical manufacturing.

INTRODUCTION

The Gram-positive soil bacterium *Arthrobacter nicotinovorans* pAO1 acquired the metabolic capacity to metabolize the tobacco alkaloid nicotine as an exclusive carbon source. Utilization is initiated by hydroxylation of nicotine’s pyridine ring at position C6 followed by oxidation mediated by the 6-hydroxy-nicotine oxidase (6HNO). Recent sequence analysis of the catabolic plasmid pAO1 revealed the 6HNO gene repressor HdnoR, which controls 6HNO expression in the presence of 6-hydroxy-nicotine (6HNic) (1). 6HNic modulates HdnoR’s allosteric conformation in a way that prevents further binding and repression of the 6HNO promoter, thereby resulting in induction of follow-up nicotine-specific metabolic...
pathways, 6HNic produced by *A. nicotinovorans* pAO1 came into the limelight as a bio-catalytic bulk product, which can be employed in conventional esterification processes or as an educt for the production of particular special chemicals, including 6-alkoxynicotine derivatives known to exhibit antibacterial and antifungal activities (2). In addition to being an intermediate product in (bio-) chemical production scenarios, 6HNic is also a by-product of pioneering efforts to denicotinize tobacco for the production of ‘mild’ or ‘light’ cigarettes characterized by a low nicotine content (3,4). Besides its involvement in the aforementioned processes, knowledge of 6HNic’s physiologic impact and pharmacokinetics is limited or non-existing. However, unlike nicotine itself, 6HNic is expected to be more soluble and unable to trigger nicotine-specific receptor responses because of its hydroxylated aromatic ring (5).

HdnOR has been reported to belong to the TetR family of bacterial response regulators, which repress target genes in a physiologic compound-responsive manner (1). In particular, TetR dissociates from a cognate P_{tetA} promoter in the presence of tetracycline antibiotics and so induces the expression of the tetracycline resistance gene tetA (6). Pioneering efforts in using bacterial response regulators for mammalian transgene expression fine-tuning have resulted in the design of the tetracycline-responsive expression system [the TET system(s)], which consists of its generic configuration of TetR fused to a Herpes simplex-derived VP16 transactivation domain (tTA) and a heptameric TetR-specific tetA promoter-derived operator module (tetO7) functionally linked to the minimal version of the human cytomegalovirus immediate early promoter (tetO3-P_{ICMVmin}: P_{ICMV}^\text{−\textendash}1). tTA binding to P_{ICMV}^\text{−\textendash}1 induced desired transgene transcription in the absence of tetracycline. However, tetracycline switched tTA’s allosteric conformation to a P_{ICMV}^\text{−\textendash}1 binding-incompetent state, which resulted in dose-dependent transgene repression (7).

Following the generic design principle of the TET system, a wide variety of bacterial response regulators have been adapted for use as mammalian gene regulation systems, including those responsive to (i) tetracycline derivatives (7,8), (ii) streptogramin (9), (iii) macrolide (10) and (iv) coumermycin (11) antibiotics, (v) immunosuppressive rapamycin (12), hormones such as (vi) estrogen (13), (vii) progesterone (14) and (viii) ecdysone (15), (ix) temperature (16), (x) quorum-sensing molecules (17,18), (xi) the tetrpene cumate (http://www.qbiogene.com/products/gene-expression/qmateslideshow/index.htm), (xii) the type-2 diabetes drug rosiglitazone (19) and (xiii) gaseous acetaldehyde (20).

Most transgene regulation modalities were conceived or have been used as stand-alone systems [one-gene control system modulating a single (set) of transgene(s)] for targeted molecular interventions in complex regulatory networks, including (i) prototype gene therapy and tissue engineering scenarios (12,21), (ii) drug discovery (22,23), (iii) biopharmaceutical manufacturing (24,25) and (iv) gene-function analysis (26). Clinically licensed antibiotics (macrolide, streptogramin, coumermycin and tetracycline), immunosuppressive agents (rapamycin), hormones (mifepristone) and PPAR-γ (peroxisome proliferator-activated receptor-γ) agonists (rosiglitazone) seem to be ideal candidates for gene therapy-based conditional transgene interventions. However, some of these drugs may elicit side effects following long-term administration at regulation-effective concentrations (27–29). Furthermore, drug-based inducers are less suited for transgene modulation of biotechnologically relevant production cell lines, since preparation of inducer-free product formulations remains a costly downstream processing challenge.

Availability of different compatible transgene regulation systems enabled their functional interconnection to produce synthetic mammalian networks with unprecedented signal integration. The most prominent mammalian cell-embedded synthetic regulatory networks include: (i) an artificial regulatory cascade consisting of three heterologous transcription control units interconnected in a linear manner to produce discrete multilevel expression control of a terminally encoded transgene in response to clinical doses of different antibiotics (30), (ii) an epigenetic circuitry able to switch between two stable transgene expression states after transient administration of two alternate drugs (31) and BioLogic gates providing transgene expression integration reminiscent of digital electronics (32).

We have designed a novel gene regulation system [6HNic-adjustable transgene expression (NICE)] responsive to the non-toxic nicotine derivative 6HNic. NICE technology enabled fine-tuning of transgene expression in mammalian cells, was compatible with state-of-the-art lentiviral transduction and provided precise control of angiogenic responses in chicken embryos. Since NICE systems are responsive to a clinically inert, highly water-soluble nicotine derivative, we believe it will foster advances in basic research as well as in biopharmaceutical manufacturing.

**MATERIALS AND METHODS**

**Plasmid construction**

All plasmids used in this study are listed in Table 1; detailed information on their construction is also provided.

**Cell culture and transfection**

Chinese hamster ovary cells (CHO-K1, ATCC CCL 61) were cultivated in standard medium: FMX-8 medium (Cell Culture Technologies, Zurich, Switzerland) supplemented with 10% fetal calf serum (FCS) (Pan Biotech GmbH, Aidenbach, Germany; catalog no. 3302-P231902, lot no. P231902). Human embryonic kidney cells transgenic for simian virus 40 (SV40) large T antigen [HEK293-T (33)] were cultivated in DMEM (Invitrogen, Carlsbad, CA) supplemented with 10% FCS. All cell lines were cultivated at 37°C in a 5% CO2-containing humidified atmosphere. CHO-K1 cells were transfected using an optimized calcium phosphate-based protocol that resulted in standard transfection efficiencies of 35 ± 5%. In brief, 40 000 CHO-K1 cells were seeded per well of a 24-well plate and cultivated overnight. Aliquots containing 6 μg of plasmid DNA (for cotransfections equal amounts of each plasmid were used) were diluted in 60 μl of 250 mM CaCl2 and precipitated following drop-wise addition of 60 μl phosphate solution for 20 s (50 mM HEPES, 280 mM NaCl, 1.5 mM Na2HPO4, pH 7.1). Following further incubation for 10 s, 2 ml FMX-8 containing 2% FCS were added. The culture medium was replaced by the DNA-precipitate-containing
Table 1. Plasmids used and designed in this study

| Plasmid        | Description and cloning strategy                                                                 | Reference or source |
|----------------|---------------------------------------------------------------------------------------------------|---------------------|
| pH6EX3-HdnoR   | Vector encoding the *A. nicotinovarans* pAO16 repressor of the 6Hnic oxidase (HdnoR)             | (1)                 |
| pLM82          | Constitutive NT1 expression vector (pSV40/NT1-pA; NT1, HdnoR-VP16) This work                    |                     |
| pLM102         | Constitutive NT3 expression vector (pSV40/NT3-pA; NT3, HdnoR-E2F4) This work                    |                     |
| pLM103         | Lentiviral NT1 expression vector (5’LTR-VP16-PPT-RE-PhEF1-NT1-3’LTR-ΔU3) NT1, HdnoR-VP16 This work |                     |
| pLM104         | Lentiviral expression vector encoding a PNC1c-driven SEAP expression unit (PNC1c-SEAP-pA; PNC1c, O NIC-4bp-PhCMVmin) This work |                     |
| pLM105         | Lentiviral expression vector encoding a PNC1d-driven SEAP expression unit (PNC1d-SEAP-pA; PNC1d, O NIC-6bp-PhCMVmin) This work |                     |
| pLM106         | Lentiviral expression vector encoding a PNC1e-driven SEAP expression unit (PNC1e-SEAP-pA; PNC1e, O NIC-8bp-PhCMVmin) This work |                     |
| pLM107         | Lentiviral expression vector encoding a PNC1f-driven SEAP expression unit (PNC1f-SEAP-pA; PNC1f, O NIC-10bp-PhCMVmin) This work |                     |
| pLM83          | Vector encoding a PNC1l-driven SEAP expression unit (PNC1l-SEAP-pA; PNC1l, O NIC-8bp-P CMVmin) This work |                     |
| pLM84          | Vector encoding a PNC1m-driven SEAP expression unit (PNC1m-SEAP-pA; PNC1m, O NIC-10bp-P CMVmin) This work |                     |
| pBM104         | Lentiviral expression vector encoding a PIR8-driven VEGF121 expression unit (5’LTR-IR8-PPT-RE-EYFP-3’LTR-ΔU3) This work | (68)               |
| pBM105         | Lentiviral expression vector encoding a PIR8-driven SEAP expression unit (5’LTR-IR8-PPT-RE-P CMVmin-3’LTR-ΔU3) This work | (68)               |
| pBP10          | Vector encoding a PET5-driven SEAP expression unit (PET5-SEAP-pA; PET5, ETR-2bp-PhCMVmin) This work | (47)               |
| pBP11          | Vector encoding a PET6-driven SEAP expression unit (PET6-SEAP-pA; PET6, ETR-4bp-PhCMVmin) This work | (47)               |
| pBP12          | Vector encoding a PET7-driven SEAP expression unit (PET7-SEAP-pA; PET7, ETR-8bp-PhCMVmin) This work | (47)               |
| pBP13          | Vector encoding a PET8-driven SEAP expression unit (PET8-SEAP-pA; PET8, ETR-10bp-PhCMVmin) This work | (47)               |
| pBP14          | Vector encoding the *A. nicotinovarans* pAO16 repressor of the 6Hnic oxidase (HdnoR)             |                     |
| pBM104         | Lentiviral expression vector encoding a PIR8-driven VEGF121 expression unit (5’LTR-IR8-PPT-RE-EYFP-3’LTR-ΔU3) This work | (33)               |
| pBM105         | Lentiviral expression vector encoding a PIR8-driven SEAP expression unit (5’LTR-IR8-PPT-RE-P CMVmin-3’LTR-ΔU3) This work | (33)               |
| pBP10          | Vector encoding a PET5-driven SEAP expression unit (PET5-SEAP-pA; PET5, ETR-2bp-PhCMVmin) This work | (47)               |
| pBP11          | Vector encoding a PET6-driven SEAP expression unit (PET6-SEAP-pA; PET6, ETR-4bp-PhCMVmin) This work | (47)               |
| pBP12          | Vector encoding a PET7-driven SEAP expression unit (PET7-SEAP-pA; PET7, ETR-8bp-PhCMVmin) This work | (47)               |
| pBP13          | Vector encoding a PET8-driven SEAP expression unit (PET8-SEAP-pA; PET8, ETR-10bp-PhCMVmin) This work | (47)               |
| pBP14          | Vector encoding the *A. nicotinovarans* pAO16 repressor of the 6Hnic oxidase (HdnoR)             | (1)                 |

This work
### Table 1. Continued

| Plasmid | Description and cloning strategy | Reference or source |
|---------|----------------------------------|---------------------|
| pLM123  | AscI-Stul-Aattf-Xbal-ONic-10bp-Nhel-Sbfl-Ecorl-Epo = PCR-amplified from pWW139 using oLM95 | This work |
| pLM124  | ONic-Nhel-Sbfl-Ecorl-Epo = excised from pLM116 using XbaI/ClaI and ligated into the corresponding sites (AscI/Clal) of pLM116. | This work |
| pLM125  | ONic-Nhel-Sbfl-Ecorl-Epo = excised from pLM116 using XbaI/ClaI and ligated into the corresponding sites (AscI/Clal) of pLM116 | This work |
| pLM126  | ONic-Nhel-Sbfl-Ecorl-Epo = excised from pLM116 using XbaI/ClaI and ligated into the corresponding sites (AscI/Clal) of pLM116 | This work |
| pLM127  | ONic-Nhel-Sbfl-Ecorl-Epo = excised from pLM116 using XbaI/ClaI and ligated into the corresponding sites (AscI/Clal) of pLM116 | This work |
| pLM128  | ONic-Nhel-Sbfl-Ecorl-Epo = excised from pLM116 using XbaI/ClaI and ligated into the corresponding sites (AscI/Clal) of pLM116 | This work |
| pLM129  | pCMV-ONIC2-0bp-ONIC1-Nhel was excised from pWW139 using ScaI/SbfI and ligated into the corresponding sites (AscI/EcoRI) of pBM105, thereby resulting in P hCMV-ONIC2-0bp-ONIC1-Nhel-Sbfl-Ecorl-Epo-SEAP-pA | This work |
| pLM130  | pCMV-ONIC2-10bp-ONIC1-Nhel was excised from pWW139 using ScaI/SbfI and ligated into the corresponding sites (AscI/EcoRI) of pBM105, thereby resulting in P hCMV-ONIC2-10bp-ONIC1-Nhel-Sbfl-Ecorl-Epo-SEAP-pA | This work |
| pLM131  | pCMV-ONIC2-8bp-ONIC1-Nhel was excised from pWW139 using ScaI/SbfI and ligated into the corresponding sites (AscI/EcoRI) of pBM105, thereby resulting in P hCMV-ONIC2-8bp-ONIC1-Nhel-Sbfl-Ecorl-Epo-SEAP-pA | This work |
| pLM132  | pCMV-ONIC2-6bp-ONIC1-Nhel was excised from pWW139 using ScaI/SbfI and ligated into the corresponding sites (AscI/EcoRI) of pBM105, thereby resulting in P hCMV-ONIC2-6bp-ONIC1-Nhel-Sbfl-Ecorl-Epo-SEAP-pA | This work |
| pLM133  | pCMV-ONIC2-4bp-ONIC1-Nhel was excised from pWW139 using ScaI/SbfI and ligated into the corresponding sites (AscI/EcoRI) of pBM105, thereby resulting in P hCMV-ONIC2-4bp-ONIC1-Nhel-Sbfl-Ecorl-Epo-SEAP-pA | This work |
| pLM134  | pCMV-ONIC2-2bp-ONIC1-Nhel was excised from pWW139 using ScaI/SbfI and ligated into the corresponding sites (AscI/EcoRI) of pBM105, thereby resulting in P hCMV-ONIC2-2bp-ONIC1-Nhel-Sbfl-Ecorl-Epo-SEAP-pA | This work |
| pLM135  | Vector encoding a P NIC2d-driven SEAP expression unit (P NIC2d-SEAP-pA; P NIC2d, ONIC2-6bp-ONIC1-Nhel-Sbfl-Ecorl-Epo-SEAP-pA) | This work |
| pLM136  | Vector encoding a P NIC2c-driven SEAP expression unit (P NIC2c-SEAP-pA; P NIC2c, ONIC2-4bp-ONIC1-Nhel-Sbfl-Ecorl-Epo-SEAP-pA) | This work |
| pLM137  | Vector encoding a P NIC2b-driven SEAP expression unit (P NIC2b-SEAP-pA; P NIC2b, ONIC2-2bp-ONIC1-Nhel-Sbfl-Ecorl-Epo-SEAP-pA) | This work |
| pLM138  | Vector encoding a P NIC2a-driven SEAP expression unit (P NIC2a-SEAP-pA; P NIC2a, ONIC2-0bp-ONIC1-Nhel-Sbfl-Ecorl-Epo-SEAP-pA) | This work |
| pLM139  | Vector encoding a P NIC2d-driven SEAP expression unit (P NIC2d-SEAP-pA; P NIC2d, ONIC2-6bp-ONIC1-Nhel-Sbfl-Ecorl-Epo-SEAP-pA) | This work |
| pLM140  | Vector encoding a P NIC2c-driven SEAP expression unit (P NIC2c-SEAP-pA; P NIC2c, ONIC2-4bp-ONIC1-Nhel-Sbfl-Ecorl-Epo-SEAP-pA) | This work |
| pLM141  | Vector encoding a P NIC2b-driven SEAP expression unit (P NIC2b-SEAP-pA; P NIC2b, ONIC2-2bp-ONIC1-Nhel-Sbfl-Ecorl-Epo-SEAP-pA) | This work |
| pLM142  | Vector encoding a P NIC2a-driven SEAP expression unit (P NIC2a-SEAP-pA; P NIC2a, ONIC2-0bp-ONIC1-Nhel-Sbfl-Ecorl-Epo-SEAP-pA) | This work |
| pLM143  | Vector encoding a P NIC2d-driven SEAP expression unit (P NIC2d-SEAP-pA; P NIC2d, ONIC2-6bp-ONIC1-Nhel-Sbfl-Ecorl-Epo-SEAP-pA) | This work |
| pLM144  | Vector encoding a P NIC2c-driven SEAP expression unit (P NIC2c-SEAP-pA; P NIC2c, ONIC2-4bp-ONIC1-Nhel-Sbfl-Ecorl-Epo-SEAP-pA) | This work |
| pLM145  | Vector encoding a P NIC2b-driven SEAP expression unit (P NIC2b-SEAP-pA; P NIC2b, ONIC2-2bp-ONIC1-Nhel-Sbfl-Ecorl-Epo-SEAP-pA) | This work |
| pWW39   | Constitutive ET1 expression vector (P SV40-ET1-pA) | Clontech, Palo Alto, CA |
| pWW42   | Constitutive ET2 expression vector (P SV40-ET2-pA) | Clontech, Palo Alto, CA |
| pWW64   | Constitutive ET4 expression vector (P SV40-ET4-pA) | Clontech, Palo Alto, CA |
| pWW139  | Epo expression vector | Clontech, Palo Alto, CA |

---

3'LTR, enhancer-free 3' long terminal repeat; 5'LTR, 5' long terminal repeat; 6HNic, 6-hydroxy-nicotine; cPTT, central polypurine tract; E2f4, human transcription factor, transactivation domain of the human E2f4; Epo, erythropoietin; ETr2, macrolide-dependent transactivator (MphR(A)-VP16); ET2, macrolide-dependent transactivator (MphR(A)-PNIC2d); 6HNic, 6-hydroxy-nicotine; HDMO, repressor of the Nicotiana tabacum pAO1 6HNic oxidase gene; MphR(A), E.coli-driven repressor of the macrolide resistance gene mphA; NF-kb, human transcription factor; NT1, 6HNic-dependent transactivator (Hdno-R-VP16); NT2, 6HNic-dependent transactivator (Hdno-R-p65); NT3, 6HNic-dependent transactivator (Hdno-R-E2F4); ONic, Hdno-specific operator; O Nic1/2, ONic numbering in tandem operator configurations; oLM95, origin of replication of the SV40; p5, transactivation domain of the human E2F4; pA, SV40-derived polyadenylation site; pET2, macrolide-responsive promoter (ETR-PNIC2d); PETR, a macrolide-responsive promoters containing different spacers between ETR and PNIC2d-PNIC3, promoter of the human cytomegalovirus immediate early promoter, minimal promoter of the human elongation factor 1 alpha; P NIC1-5, 6HNic-responsive promoters containing different spacers between ONIC and P NIC1-5-6HNic-responsive promoters containing different spacers between ONIC and P NIC1-5; P NIC2a, 6HNic-responsive promoter with extended spacing between ONIC and P NIC2a-6HNic-responsive promoter with extended spacing between ONIC and P NIC2a-RRE, rev response element; SEAP, human placental secreted alkaline phosphatase; VEGF121, human vascular endothelial growth factor 121; VSV, extended lentiviral packaging domain; **y**+, extended lenti-packaging signal.
medium and incubated for 5 h prior to a glycerol shock for 30 s (FMX-8 medium supplemented with 15% glycerol and 2% FCS). After a single washing step using standard medium, cells were cultivated for analysis in the presence or absence of regulating 6HNic (50 μg/ml, unless stated otherwise). Forty-eight hours post glycerol shock, reporter protein expression was profiled.

**Lentiviral particle production and transduction**

For production of replication-incompetent self-inactivating HIV-1-derived lentiviral particles, HEK293-T cells were co-transfected following an optimized calcium phosphate-based protocol. In brief, 200,000 HEK293-T cells were seeded per well of a 6-well plate and cultivated overnight in 2 ml 10% FCS-containing DMEM. For each transfection, 1 ml per well of a 6-well plate and cultivated overnight in 2 ml 10% FCS-containing DMEM. The cells were transduced with a lentiviral expression vector which were diluted in 100 mM Na₂HPO₄, pH 7.1, 1 μg pLTR-G encoding the pseudotyping envelope protein VSV-G of the vesicular stomatitis virus (34), 1 μg pCD/NL-BH* [helper construct (35)] and 1 μg of the desired transgene-encoding lentiviral expression vector were diluted in 100 μl of 250 mM CaCl₂. The DNA mixture was added drop-wise to 100 μl phosphate solution (100 mM HEPES, 280 mM NaCl, 1.5 mM Na₂HPO₄, pH 7.1), incubated for 15 min to enable formation of DNA-CaPO₄ precipitates, which were subsequently added to HEK293-T cultures. Five-hours post-transfection, the DNA-CaPO₄ complex was removed by medium exchange and lentiviral particles were produced for another 48 h prior to collection from the supernatant by filtration through a 0.45 μm filter (PIR8FP 030/2; Schleicher & Schuell GmbH, Dassel, Germany). This protocol typically yielded lentiviral particle titer of 2 × 10^5 c.f.u./ml following titration on CHO-K1 cells or enzyme-linked immunosorbent assay-based p24 quantification according to the manufacturer’s protocol (catalog no. 103; ImmunoDiagnostics Inc., Woburn, MA). In order to prevent cross-contamination of secreted proteins from production supernatants and increase overall transduction efficiency, lentiviral particles were concentrated by ultracentrifugation for 2 h at 43,000 g and 4°C (Beckman Quick-Seal centrifuge tubes; catalog no. 342413, Beckman Instruments Inc., CA). The pellets were resuspended in 10% FCS-containing DMEM to adjust viral concentrations to desired levels. Furthermore, the culture medium was exchanged 6 h post transduction to ensure that transgene expression was exclusively based on transduction. Unless stated otherwise, standard transduction experiments included infection of 24,000 target cells seeded per well of a 12-well plate with 8 × 10^5 c.f.u. lentiviral particles (4 ng of p24).

**Quantification of reporter protein production**

Product proteins were quantified in cell culture supernatants 48 h after transduction. Human placental secreted alkaline phosphatase (SEAP) production was assessed using a chemiluminescence-based assay (Roche Diagnostics AG, Rotkreuz, Switzerland). Human vascular endothelial growth factor 121 (VEGF₁₂₁) production was quantified using the human VEGF-specific DuoSet ELISA System (R&D Systems, Minneapolis, MO) according to the manufacturer’s protocol.

**In vivo methods I—mice**

CHO-K1 cells engineered for NICE-controlled SEAP expression by cotransfection of pLM82 (Psv40-NT1-pA) and pLM104 (PNIC18-SEAP-pA) were encapsulated in coherent alginate-poly-(L-lysine)-alginate beads (200 cells/capsule, 2 × 10⁶ cells/mouse) as described previously (10) and implanted intraperitoneally into female OFI mice (oncins France souche 1; Iffa-Credo, Lyon, France). At 1 h after capsule implantation, 6HNic was administered by intraperitoneal injection at doses ranging from 0 to 100 mg/kg. 6HNic was formulated for in vivo administration by dilution of stock solutions to appropriate concentrations using physiological salt solution [0.9% (w/v); Laboratoire Aguettant, Lyon, France]. Control mice harbored encapsulated wild-type CHO-K1 cells. At 72 h after 6HNic administration, the mice were killed for blood collection and quantification of SEAP serum levels using microtainer SST tubes (Beckton Dickinson, Plymouth, UK) according to the manufacturer’s protocol. All experiments involving mice were approved by the French Ministry of Agriculture and Fishery (Paris, France) and performed by M. D. El-Baba at the Institut Universitaire de Technologie, IUTA, F-69622 Villeurbanne Cedex, France.

**In vivo methods II—transduction of chicken embryos**

The shell-free cultivation protocols of Djonov and co-workers (36) were used for all experiments involving chicken embryos. Brown Leghorn eggs were opened after 3 days incubation at 37°C and their contents were carefully poured into 80 mm plastic Petri dishes. The chicken embryos were incubated at 37°C in a humidified atmosphere. On embryonic day 9, pLM146- (100 μl in DMEM, 8.5 × 10⁵ c.f.u., 40 ng p24) and pLM103- (90 μl in DMEM, 6.4 × 10⁵ c.f.u., 3 ng p24) derived lentiviral particles were co-applied locally on top of the growing chorioallantoic membrane (CAM) together with 0.5 μl (0.5 mM in DMEM) CellTracker orange CMTMR (catalog no. C-2927; Molecular Probes Inc., Eugene, OR) to identify the transduction site. In order to modulate heterologous VEGF₁₂₁ expression, different concentrations of 6HNic (0, 0.1, 1 and 50 μg/ml) were administered 1 h post transduction. On embryonic day 12, the CAMs were examined by in vivo fluorescence microscopy following intravenous injection of 100 μl 2.5% fluorescein isothiocyanate dextran (FITC) (2,000,000; Sigma Chemicals, Saint Louis, MO) (37). FITC-stained CAM blood vessels were visualized at 50× and 100× magnifications using a Leica DM-RE fluorescent microscope equipped with a Leica digital fluorescence camera DC300 FX (Leica Microsystems AG, Heerbrugg, Switzerland) and a XF114 filter (Omega Optical Inc., Brattleboro, VT).

**HPLC-based quantification of 6-hydroxy-nicotine**

6HNic concentrations in 2 μl mouse urine samples were quantified by high-performance liquid chromatography (HPLC) [reversed-phase C18 column (Atlantis® C18, 4.6 × 150 mm; Waters Associates Inc.), Waters 2695 Separation Module (Waters Associates Inc.), Waters 996 Photodiode Array Detector (Waters Associates Inc.)]. Using an isocratic elution system of 0.1% TFA in water/acetonitrile (98:2 v/v) at a flow rate of 1 ml/min, the retention time of 6HNic was 7.1 min. The chromatograms were analyzed at 230 and 295 nm using Waters Empower® software. 6HNic concentrations in each sample were determined based on a peak area calibration curve generated using pure 6HNic.
Regulating 6-hydroxy-nicotine

6HNic (InterBioScreen, Moscow, Russia) was prepared as a stock solution of 100 mg/ml in water and used at indicated final concentrations.

RESULTS

Design of the 6-hydroxy-nicotine-responsive mammalian transgene regulation system

Capitalizing on machinery enabling A.nicotinovorans pAO1 to metabolize nicotine, we have designed a system called NICE. NICE-controlled transgene modulation in mammalian cells required two functionally crosstalkling components: (i) an artificial transactivator (NT1) engineered by fusing A.nicotinovorans pAO1’s 6-hydroxy-D-nicotine oxidase gene (6HDNO) repressor HdnoR to the generic H.simples type 1 (HSV-1) VP16 transactivation domain (1,38) (pLM82; PSV40-NT1-pA, NT1, HdnOR-VP16) and (ii) a chimeric promoter (PNIC) assembled by cloning 6HDNO-specific operator modules (ONIC) adjacent to a minimal version of the human cytomegalovirus immediate early promoter (PhCMVmin; PNIC, ONIC-10bp-PhCMVmin) (1,39). Following cotransfection of pLM82 (Psv40-NT1-pA) and pLM83 (PNIC–SEAP-pA; PNIC1a, ONIC-0bp-PhCMVmin), enabling PNIC1a-driven human placental SEAP expression, into CHO–K1 grown in the absence of 6HNic, NT1 bound PNIC1a via HdnOR–ONIC interaction and initiated high-level SEAP production (48.0 ± 7.3 U/l). Akin to 6HNic-mediated derepression of 6HDNO in A.nicotinovorans pAO1 NT1 adopts a binding-incompetent allosteric conformation in the presence of 6HNic, which results in disruption of the NT1–PNIC1a interaction and shutdown of SEAP production (1.3 ± 0.2 U/l) (Figure 1).

6HNic-responsive promoter configurations I—PNIC containing a single NT1-specific operator

Efficient transcription-initiation of regulated promoters requires optimal crosstalk between the transcription machinery, the transactivator tethered to the cognate operator and the minimal promoter. The distance and twist between the operator module and the minimal promoter represent spatio-steric constraints for the assembly of the transcription-translation initiation complex and so influence overall performance of regulated promoters (40–46). With the aim of designing optimal PNIC configurations, we engineered linkers of 2 bp increments ranging from 0 to 10 bp between ONIC and PhCMVmin (PNIC1a, ONIC-0bp-PhCMVmin; PNIC1b, ONIC-2bp-PhCMVmin; PNIC1c, ONIC-4bp-PhCMVmin; PNIC1d, ONIC-6bp-PhCMVmin; PNIC1e, ONIC-8bp-PhCMVmin; PNIC1f, ONIC-10bp-PhCMVmin). PNIC1a-f-driven SEAP expression units (PNIC1a, pLM83; PNIC1b, pLM104; PNIC1c, pLM105; PNIC1d, pLM106; PNIC1e, pLM107; PNIC1f, pLM108) were cotransfected with the NT1 expression vector pLM82 (PSV40-NT1-pA) into CHO–K1 and cultivated for 48 h in the presence (50 µg/ml 6HNic) and absence of 6HNic before SEAP production was quantified. The PSV40-driven SEAP expression used as the control indicated that 6HNic showed no negative impact on host cell physiology at regulation-effective concentrations (Figure 2A). PNIC1b harboring 2 bp between ONIC and PhCMVmin showed the tightest repression of all promoter configurations while its maximum SEAP expression levels compared favorably with PSV40. Although PNIC1c and PNIC1f promoted higher SEAP production compared with PNIC1b, their leaky expression was increased as well. Direct comparison of the isogenic promoters PNIC1a and PNIC1f, which harbor ONIC and PhCMVmin on the same face of the DNA but at different distances, suggested a distance-dependent increase of both maximum as well as leaky expression (Figure 2A).

In order to assess the dose-response characteristics of the NICE technology, CHO–K1 were cotransfected with pLM104 (PNIC1b–SEAP-pA) and pLM82 (PSV40–NT1–pA) and cultivated for 48 h in the presence of increasing 6HNic concentrations prior to SEAP production profiling. SEAP production gradually decreased at and beyond 50 ng/ml 6HNic until transgene expression was fully repressed at 50 µg/ml 6HNic. Control configurations including PSV40-driven SEAP expression

![Figure 1. Schematic representation of key components of the 6HNic (6HNic)-responsive transgene regulation system (NICE). As a binary transcription-control system, NICE consists of an artificial 6HNic-dependent transactivator (NT), assembled by fusing the A.nicotinovorans pAO1 6HNic oxidase repressor HdnoR to functional mammalian transactivation domains (T; e.g. H.simples VP16), p65 of human NF-kB, a domain of human E2F4) and a chimeric promoter engineered by placing HdnoR-specific operator modules (ONIC) adjacent to a minimal version of the human cytomegalovirus immediate early promoter (PhCMVmin). In the absence of 6HNic (~6HNic), NT binds to PNIC via direct HdnoR–ONIC interaction and induces PhCMVmin-mediated transcription of the gene of interest (goi). However, 6HNic modifies NT’s allosteric such that it is no longer able to bind and induce PNIC, which results in complete transgene repression.](image-url)
NT1-pA) and pLM104 (P NIC1b-SEAP-pA) were cultivated for 48 h in the absence and presence of 100 μg/ml 6HNic confirming that this nicotine derivative exhibits no deleterious physiologic effects on mammalian cells at regulation-effective concentrations (Figure 3). Tandem ONIC-2 operator modules supported optimal tightness among 2-O NIC-containing promoters while transgene expression reached 2-fold higher levels compared with mono-O NIC P NIC1-containing promoters (PNIC1a, P NIC1b-SEAP-pA; pLM135, P NIC1c-SEAP-pA; pLM136, P NIC1d-SEAP-pA; pLM137, P NIC1e-SEAP-pA; pLM138, P NIC1f-SEAP-pA) and P NIC2 derivatives containing a first NT1 operator (O NIC1) at an optimal distance 5' of P hCMVmin and a second operator (O NIC2) placed 0/2/4/6/8/10 bp upstream of O NIC1 (P NIC2b, O NIC2c-spaceer-O NIC2d-Nhel-ShfI-4bp-P hCMVmin). Resulting promoters (P NIC2a, P NIC2b-0bp-O NIC2c-Nhel-ShfI-4bp-P hCMVmin; P NIC2b-2bp-O NIC2c-Nhel-ShfI-4bp-P hCMVmin; P NIC2c-0bp-O NIC2d-Nhel-ShfI-4bp-P hCMVmin; P NIC2d-0bp-O NIC2e-Nhel-ShfI-4bp-P hCMVmin; P NIC2c-6bp-O NIC2d-Nhel-ShfI-4bp-P hCMVmin; P NIC2e-0bp-O NIC2f-Nhel-ShfI-4bp-P hCMVmin) were configured for SEAP expression (pLM135, P NIC2a-SEAP-pA; pLM136, P NIC2b-SEAP-pA; pLM137, P NIC2c-SEAP-pA; pLM138, P NIC2d-SEAP-pA; pLM139, P NIC2e-SEAP-pA; pLM140, P NIC2f-SEAP-pA) and cotransfected with the NT1 expression vector pLM82 (P SV40-NT1-pA; NT1, HdnoR-VP16) into CHO-K1 and cultivated for 48 h in the presence (50 μg/ml 6HNic) and absence of 6HNic before SEAP production was quantified. SEAP production was compared with pSEAP-Control-transfected CHO-K1 cells harboring a glycoprotein expression unit driven by the constitutive SV40 promoter (P SV40).

in CHO-K1 reached identical glycoprotein production in the absence and presence of 100 μg/ml 6HNic confirming that this nicotine derivative exhibits no deleterious physiologic effects on mammalian cells at regulation-effective concentrations (Figure 2B).

6HNic-responsive promoter configurations II—P NIC containing a tandem NT1-specific operator

In order to increase the expression performance of P NIC1b, we cloned a second O NIC (O NIC2) module 5' of O NIC1. P NIC2 derivatives contain a first NT1 operator (O NIC1) at an optimal distance 5' of P hCMVmin and a second operator (O NIC2) placed 0/2/4/6/8/10 bp upstream of O NIC1. The line was added for clarity.}

Figure 2. Regulation performance and adjustability of 6HNic-responsive promoters (P NIC1) containing a single 6HNic-dependent transactivator (NT)-specific operator module. (A) 6HNic-responsive promoters containing a single operator module (O NIC) were engineered to contain linkers of 2 bp increments ranging from 0 to 10 bp between O NIC and the minimal promoter P hCMVmin (P NIC1a, O NIC-0bp-P hCMVmin; P NIC1b, O NIC-2bp-P hCMVmin; P NIC1c, O NIC-4bp-P hCMVmin; P NIC1d, O NIC-6bp-P hCMVmin; P NIC1e, O NIC-8bp-P hCMVmin; P NIC1f, O NIC-10bp-P hCMVmin). P NIC1a-f-driven SEAP expression units (P NIC1a-SEAP-pA [pLM106]; P NIC1b-SEAP-pA [pLM107]; P NIC1c-SEAP-pA [pLM108]; P NIC1d-SEAP-pA [pLM109]; P NIC1e-SEAP-pA [pLM110]; P NIC1f-SEAP-pA [pLM111]) were cotransfected with the NT1 expression vector pLM82 (P SV40-NT1-pA; NT1, HdnoR-VP16) into CHO-K1 and cultivated for 48 h in the presence and absence of 100 μg/ml 6HNic prior to SEAP quantification (Figure 3). Tandem O NIC-containing modules doubled maximum SEAP expression levels compared with mono-O NIC P NIC1-containing promoter derivatives. However, leaky transcription in the presence of 6HNic was also increased, which compromised overall regulation performance. P NIC2-containing 6 bp between the two O NIC modules supported optimal tightness among 2-O NIC-containing promoters while transgene expression reached 2-fold higher levels compared with P NIC1b (Figures 2 and 3). Direct correlation between the number of tandem operator modules and maximum expression levels is a common observation for transcription control modalities of the NICE type. Also, a qualitative correlation between maximum and leaky expression is
frequently observed (47). Generic $P_{NIC1}$ and $P_{NIC2}$ promoters offer a wide portfolio of transgene regulation performance and provide a choice of specific expression/regulation characteristics, depending on the gene regulation system’s mission.

**Engineering of different 6HNic-dependent transactivators**

In addition to rigorous engineering of 6HNic-responsive promoters, we designed 6HNic-dependent transactivators containing alternative transcription domains. We selected the potent transactivation domains of NF-κB (p65) and E2F4 (E2F4), which showed efficient transactivation in antibiotic-adjustable transgene regulation settings (47–51). VP16 of NT1 was replaced by p65 and E2F4 transactivation domains, which resulted in NT2 (HdnR-p65) and NT3 (HdnR-E2F4), respectively. The relative transactivation properties of NT1, NT2 and NT3 were assessed by cotransfection of either pLM82 ($P_{SV40}$-NT1-pA), pLM101 ($P_{SV40}$-NT2-pA) or pLM102 ($P_{SV40}$-NT3-pA) and pLM104 ($P_{NIC1b}$-SEAP-pA) into CHO-K1 followed by cultivation for 48 h in the presence and absence of 6HNic and SEAP quantification (Figure 4). Although all transactivators mediated comparable basal expression levels, their maximum transgene production levels differed significantly. NT2’s transactivation efficiency was lower compared with NT1 but higher than NT3. Thus, 6HNic-dependent transactivators showed graded transcription-initiation capacity and provided a choice of different expression windows.

**Development of 6HNic-adjustable lentivectors**

In order to enable straightforward one-step engineering of mammalian cells for NICE-controlled transgene expression, we have designed a set of HIV-1-derived self-inactivating enhancer-promoters, we designed 6HNic-dependent transactivators containing alternative transactivation domains derived from (i) $H$.simplex virus (VP16; NT1, HdnR-VP16), (ii) human NF-κB (p65; NT2, HdnR-p65) and (iii) human E2F4 (E2F4; NT3, HdnR-E2F4). The regulation performance of NT1, NT2 and NT3 was assessed by cotransfection of either pLM82 ($P_{SV40}$-NT1-pA), pLM101 ($P_{SV40}$-NT2-pA) or pLM102 ($P_{SV40}$-NT3-pA) and pLM104 ($P_{NIC1c}$-SEAP-pA) into CHO-K1 followed by cultivation for 48 h in the presence and absence of 6HNic and SEAP quantification. SEAP production was compared with pSEAP2-Control-transfected CHO-K1 cells harboring a glycoprotein expression unit driven by the constitutive SV40 promoter ($P_{SV40}$).

![Figure 4](image.png)

**Figure 4.** Regulation performance of different 6HNic-dependent transactivators. *A. nicotineovorans* pAO1’s 6HNic oxidase repressor HdnR was fused to different transcription domains derived from (i) $H$.simplex virus (VP16; NT1, HdnR-VP16), (ii) human NF-κB (p65; NT2, HdnR-p65) and (iii) human E2F4 (E2F4; NT3, HdnR-E2F4). The regulation performance of NT1, NT2 and NT3 was assessed by cotransfection of either pLM82 ($P_{SV40}$-NT1-pA), pLM101 ($P_{SV40}$-NT2-pA) or pLM102 ($P_{SV40}$-NT3-pA) and pLM104 ($P_{NIC1c}$-SEAP-pA) into CHO-K1 followed by cultivation for 48 h in the presence and absence of 6HNic and SEAP quantification. SEAP production was compared with pSEAP2-Control-transfected CHO-K1 cells harboring a glycoprotein expression unit driven by the constitutive SV40 promoter ($P_{SV40}$).

In order to alleviate possible 6HNic clearance, we cotransduced chicken embryos with lentiviral particles derived from pLM103- ($5'\text{LTR}-\psi^\text{<oriSV40>}-\text{PPT}-\text{RE1}_{\text{EF1}}-\text{NT1}-3'\text{LTR}_{\text{AU3}}$) and pLM105- ($5'\text{LTR}-\psi^\text{<oriSV40>}-\text{PPT}-\text{RE1}_{\text{EF1}}-\text{NT3}-3'\text{LTR}_{\text{AU3}}$). Cotransduction of pLM141- and pLM103-derived lentiviral particles into CHO-K1 followed by cultivation of engineered cell populations at increasing 6HNic concentrations resulted in precise dose-dependent SEAP expression fine-tuning (Figure 5A). Besides excellent adjustability, NICE-controlled SEAP production was fully reversible when followed over a 1 week period of 6HNic addition and removal alternating every 48 h. SEAP accumulation kinetics, maximum expression levels in the absence and basal expression levels in the presence of 50 μg/ml 6HNic remained reproducible following consecutive expression status switches (Figure 5B). Repeated ON–OFF or OFF–ON expression switching did neither compromise maximum nor basal expression levels.

In parallel, we studied the impact of repressed or induced expression status imprinting on follow-up expression scenarios. CHO-K1 transduced for NICE-controlled SEAP expression were set for 48 h to high (0, −6HNic) or basal (1, +6HNic) glycoprotein production, which was either maintained or switched twice during subsequent 48 h cultivation periods (48 h → 48 h → 48 h: 0 → 0 → 0, 0 → 0 → 1, 0 → 1 → 0, 0 → 1 → 1, 1 → 0 → 0, 1 → 0 → 1, 1 → 1 → 0, 1 → 1 → 1). Irrespective of the cell population’s previous NICE-controlled expression history, SEAP production levels in the presence or absence of 6HNic remained consistent (Figure 5C). Lentiviral implementation of NICE-controlled fine-tuning of transgene expression enabled stable, adjustable and reversible regulation characteristics as well as sustained regulation kinetics for over 6 days.

**In vivo validation of NICE-adjustable transgene expression in mice and chicken embryos**

For in vivo validation of NICE-adjustable transgene expression, we implanted microencapsulated CHO-K1 cells transgenic for NICE-controlled SEAP expression into coherent alginate-poly-L-lysine-algininate capsules intraperitoneally into mice (200 cells/capsule). Treated mice were exposed to different daily 6HNic doses, and serum SEAP levels were quantified 72 h after implantation. While NICE-induced SEAP production resulted in high-level concentrations of this glycoprotein in the serum of treated mice (106 ± 21 mU/l), 6HNic was unable to repress heterologous production even at concentrations of 100 mg/kg. 6HNic is a unique unphysiologic compound, which may fail to control NICE-driven gene expression due to unknown in vivo derivatization/degradation or rapid clearance from the body. Indeed, HPLC-based analysis of urine samples collected from 6HNic-treated mice showed that 90% of the administered nicotine derivative was excreted after 2 h (Figure 6). Therefore, further efforts will be required to establish NICE technology in mammals. However, the 6HNic concentration administered to mice without significant side effects remains impressive and holds promises for future applications.
VEGF121 expression cassette to modulate the chicken embryo’s vascularization in a 6HNic-adjustable manner (Figure 7). Cotransduction of these lentiviral particles into CHO-K1 followed by cultivation of infected cell populations at increasing 6HNic concentrations resulted in tight dose-dependent VEGF121 expression fine-tuning (Figure 8). Microscopic analysis of VEGF121-mediated neovascularization, as well as vessel morphology in the CAM of chicken embryos grown for 3 days at decreasing 6HNic concentrations or 6HNic-free conditions (50, 1, 0.1, 0 μg/ml, see Figure 7) showed a dose-dependent angiogenic response characterized by a general increase in blood vessel number, atypical (brush- and delta-like) endpoint patterns, irregular tortuous vessel shape and multiple vessel branching. All of those effects could be completely repressed by treating the chicken embryo with 50 μg/ml 6HNic. VEGF121-induced impact on vessel structure was confined to a 4 mm radius around the site of lentiviral particle application and could not be observed on the same CAM beyond this perimeter (Figure 7). These results confirm 6HNic-adjustable transgene transduction in vivo.

**DISCUSSION**

Long appreciated in basic sciences for their power to reveal gene-function correlations, heterologous transgene control systems have gathered momentum and now stand on the eve
of therapeutic and pilot production implementation (20,52). Currently available transcription control modalities capitalize on the generic design principle of the pioneering TET system: (i) clinically licensed tetracycline as inducer, (ii) bacterial repressor fused to mammalian cell-compatible transactivation domain as transactivator and (iii) transactivator-specific promoter assembled by fusing transactivator-specific operator modules to a minimal eukaryotic promoter. Besides their relationship to the TET configuration alternative transgene control systems differ significantly in the regulating small molecule (clinically licensed small-molecule drugs [antibiotics (7,9–11), immunosuppressive agents, (12), hormones and hormone agonists, (13–15), type-2 diabetes drug, (19,53), clinically inert compounds (17,18), temperature (16) and gaseous acetaldehyde (20)]), the origin of the transactivator [prokaryotic origin (7,9–11,16–18,20) (http://www.qbiogene.com/products/gene-expression/qmateslideshow/index.htm), mammalian origin (13,14,19,53)] and their promoter configurations [tandem operator modules, minimal promoter origin, relative promoter-operator spacing; see (40) as well as (52) for a non-limiting overview]. Despite the portfolio of different transgene regulation systems, there is nothing like the best control modality. All systems are associated with pros and cons:

(i) clinically licensed inducers are intuitively better suited for therapeutic applications, although ongoing administration of small-molecule drugs is prone to side effects,
The importance of rotational alignment of cis-acting elements on overall promoter performance has been investigated in several systems. The synthesis of those studies suggested appropriate helical phasing to be required for optimal promoter activity. Non-limiting examples included the promoter of the human serine protease B gene (54), the promoter of the Escherichia coli araBAD operon (55) and the promoter of the human HLA-DR gene (56). Furthermore, helical periodicity has been observed for promoter-enhancer crosstalk in SV40 and HIV-1 viruses (57,58). As for heterologous gene regulation systems, Weber and co-workers (47) have recently exemplified that the spacing and torsion angle between the operator and minimal promoters had dramatic impact on the overall regulation performance. This observation could be confirmed for the NICE system. Increasing the \( \text{O}_{\text{NIC}}-\text{P}_{\text{CMVmin}} \) distance by 2 bp increments resulted in a promoter portfolio with graded response characteristics.

It is commonly accepted that transactivator-mediated transcription-initiation increases with the number of cognate operator modules (59,60). Similarly, NICE promoters harboring tandem operator modules showed 2- to 3-fold higher transgene expression compared with mono-\( \text{O}_{\text{NIC}} \)-containing promoters. The net increase of the maximum expression levels was a function of the inter-\( \text{O}_{\text{NIC}} \) distance. The relative spacing between different operator modules has long been recognized as an essential factor for promoter performance (46,61–65). For example, analysis of beta interferon (IFN-\( \beta \)) gene activation showed that deletion or rearrangement of any one of the enhancer modules compromises transcription performance (66). Also, variation of the spacing between individual activator binding sites within the TCR \( \alpha \) enhancer modulated enhancer activity in a helical phasing-dependent manner (67). We have modified the inter-\( \text{O}_{\text{NIC}} \) spacing by 2 bp increments while leaving the tandem operator-minimal promoter distance invariant. Optimal spacing resulted in up to 3-fold increased maximum expression levels. However, basal expression was higher as well.

Since the transactivator interfaces with promoter and transcription-initiation machinery it has a decisive impact on the overall regulation and expression performance of transgene control modalities. We have therefore equipped HdnoR with different viral and human transactivation domains, which mediated graded response characteristics in CHO-K1.

The NICE optimization studies have resulted in a portfolio of different 6HNic-responsive promoter/transactivator configurations, which show superior key characteristics including tight repression and maximum expression levels. The choice of different promoter/transactivator combinations enables unmatched adaptation of NICE-controlled transgene expression to specific needs: tight repression is best satisfied by mono-\( \text{O}_{\text{NIC}} \)-containing promoters while promoters with tandem \( \text{O}_{\text{NIC}} \) modules support high-level transgene expression. Our rigorous NICE analysis has exemplified its potential for sophisticated cell engineering related to basic and applied research applications.

**ACKNOWLEDGEMENTS**

The authors thank Roderich Brandsch for providing pH6EX3-HdnoR. This work was supported by the Swiss National Science Foundation (grant no. 631-065946) as well as the...
Swiss State Secretariat for Education and Research within EC Framework 6. Funding to pay the Open Access publication charges for this article was provided by ETH Zurich.

Conflict of interest statement. None declared.

REFERENCES

1. Sandu,C., Chiribau,C.B. and Brandsch,R. (2003) Characterization of HdoR, the transcriptional repressor of the 6-hydroxy-N-nicotinamide gene of *Arthrobacter nicotinovorans* PA01, and its DNA-binding activity in response to 6- and N-nicotinamide derivatives. *J. Biol. Chem.*, **278**, 51307–51315.

2. Schmid,A., Dordick,J.S., Hauer,B., Kiener,A., Wubboldt,M. and Witholt,B. (2001) Industrial biocatalysis today and tomorrow. *Nature*, **409**, 258–268.

3. Brenik,W. and Rudhard,H. (1982) Patent US4343318.

4. Gravely,L.E., Geiss,V.L. and Gregory,C.F. (1985) United States Patent US4557280.

5. Yildiz,D. (2004) Nicotine, its metabolism and an overview of its biological effects. *Toxicin*, **43**, 619–632.

6. Hillen,W., Klock,G., Kaffenberger,I., Wray,L.V. and Reznikoff,W.S. (1982) Purification of the TET repressor and TET operator from the transposon Tn10 and characterization of their interaction. *J. Biol. Chem.*, **257**, 6605–6613.

7. Gossen,M. and Bujard,H. (1992) Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. *Proc. Natl Acad. Sci. USA*, **89**, 5547–5551.

8. Gossen,M., Freundlich,S., Bender,G., Muller,G., Hillen,W. and Bujard,H. (1995) Transcriptional activation by tetracyclines in mammalian cells. *Science*, **268**, 1766–1769.

9. Fussenegger,M., Morris,R.P., Fux,C., Rimann,M., von Stockar,B., Thompson,C.J. and Bailey,J.E. (2000) Streptogramin-based gene regulation systems for mammalian cells. *Nat. Biotechnol.*, **18**, 1203–1208.

10. Weber,W., Fux,C., Daoud-el Baba,M., Keller,B., Weber,C.C., Kramer,B.P., Heinzen,C., Aubel,D., Bailey,J.E. and Fussenegger,M. (2003) Macrolide-based transgene control in mammalian cells and mice. *Nat. Biotechnol.*, **20**, 901–907.

11. Zhao,H.F., Boyd,J., Jolicoeur,N. and Shen,S.H. (2003) A coumefuracin/ novobiocin-regulated gene expression system. *Hum. Gene Ther.*, **14**, 1619–1629.

12. Rivera,V.M., Clackson,T., Natesan,S., Pollock,R., Amara,J.F., Keenan,T., Magari,S.R., Phillips,T., Courage,N.L., Cerasoli,F.Jr and Phillips,J. (2000) A humanized system for pharmacologic control of gene expression in mammalian cells. *Nat. Biotechnol.*, **18**, 15266–15271.

13. Boshart,M., Weber,F., Jahn,G., Dorsch-Hasler,K., Fleckenstein,B. and Schaffner,W. (1985) An engineered epigenetic transgene switch in mammalian cells. *Nat. Biotechnol.*, **22**, 867–870.

14. Kramer,B.P., Fischer,C. and Fussenegger,M. (2004) BioLogic gates enable logical transcription control in mammalian cells. *Biotechnol. Bioeng.*, **87**, 477–484.

15. Mitta,B., Rimann,M., Ehrengruber,M.U., Ehrbar,M., Djonov,V., Kelm,J. and Fussenegger,M. (2002) Advanced modular self-inactivating lentiviral expression vectors for multigene interventions in mammalian cells and *in vivo* transduction. *Nucleic Acids Res.*, **30**, e113.

16. Boshart,M., Weber,F., Jahn,G., Dorsch-Hasler,K., Fleckenstein,B. and Schaffner,W. (1985) An engineered epigenetic transgene switch in mammalian cells. *Nat. Biotechnol.*, **22**, 867–870.

17. Kramer,B.P., Fischer,C. and Fussenegger,M. (2004) BioLogic gates enable logical transcription control in mammalian cells. *Biotechnol. Bioeng.*, **87**, 477–484.

18. Weber,W., Schoenmakers,R., Spielmann,M., da Bava,M., Far解放思想,R., Keller,B., Weber,C.C., van der Merwe,P., Heinzen,C. and Bailey,J.E. (2003) Streptomyces-derived quorum-sensing systems engineered for adjustable gene expression in mammalian cells and mice. *Nucleic Acids Res.*, **31**, e69.

19. Weber,W., Malphlettes,L., de Jesus,M., Schoenmakers,R., El-Baba,M.D., Spielmann,M., Keller,B., van der Merwe,P., Aubel,D. et al. (2004) Engineered *Streptomyces* quorum-sensing components enable inducible siRNA-mediated translation control in mammalian cells and adjustable transcription control in mice. *J. Gene Med.*, **7**, 518–525.
41. Semsey,S., Geanacopoulos,M., Lewis,D.E. and Adhya,S. (2002) Operator-bound GalR dimers close DNA loops by direct interaction: tetramerization and inducer binding. *EMBO J.*, 21, 4349–4356.

42. Sathy,G., Li,W., Klinge,C.M., Anolik,J.H., Hilf,R. and Bambara,R.A. (1997) Effects of multiple estrogen responsive elements, their spacing, and location on estrogen response of reporter genes. *Mol. Endocrinol.*, 11, 1994–2003.

43. Schreiter,E.R., Sintchak,M.D., Guo,Y., Chivers,P.T., Sauer,R.T. and Drennan,C.L. (2003) Crystal structure of the nickel-responsive transcription factor NikR. *Nature Struct. Biol.*, 10, 794–799.

44. Parkhill,J. and Brown,N.L. (1990) Site-specific insertion and deletion mutants in the mer promoter-operator region of Tn501; the nineteen base-pair spacer is essential for normal induction of the promoter by MerR. *Nucleic Acids Res.*, 18, 5157–5162.

45. Brown,N.L., Stoyanov,J.V., Kidd,S.P. and Hobman,J.L. (2003) In vitro repression of the gal promoters by GalR and HU depends on the proper helical phasing of the two operators. *J. Biol. Chem.*, 277, 2498–2504.

46. Lewis,D.E. and Adhya,S. (2002) In vitro repression of the gal promoters by GalR and HU depends on the proper helical phasing of the two operators. *J. Biol. Chem.*, 277, 2498–2504.

47. Weber,W. and Fussenegger,M. (2004) Inducible gene expression in mammalian cells and mice. *Proc. Natl Acad. Sci. USA*, 101, 15805–15810.

48. Schmitz,M.L., Stelzer,G., Altmann,H., Meisterernst,M. and Schleif,R.F. (1984) An operator-bound GalR dimers close DNA loops by direct interaction: tetramerization and inducer binding. *EMBO J.*, 21, 4349–4356.

49. Akagi,K., Kanai,M., Saya,H., Kozu,T. and Berns,A. (2001) A novel DNA binding domain of p65 NF-kappa B with TATA-binding protein, transcription factor IIB, and coactivators. *Nature Struct. Biol.*, 8, 721–726.

50. Baeuerle,P.A. (1995) Interaction of the COOH-terminal transactivation domain of p65 NF-kappa B with TATA-binding protein, transcription factor IIB, and coactivators. *J. Biol. Chem.*, 270, 7219–7226.

51. Lederer,H., Tovar,K., Baer,G., May,R.P., Hillen,W. and Heumann,H. (1989) Stereospecific alignment for repressor binding. *Comamonas testosteroni*. *J. Biol. Chem.*, 264, 9961–9970.

52. Miyamoto,M., Maller,M.I., Hillen,W. and Weiss,H. (1986) The quaternary structure of Tet repressors bound to the Tn10-encoded tet gene control region determined by neutron solution scattering. *EMBO J.*, 5, 1257–1263.

53. Merika,M., Williams,A.J., Chen,G., Collins,T. and Thanos,D. (1998) Recruitment of CBP by p300 from the IFN beta enhancer is required for synergistic activation of transcription. *Mol. Cell.*, 1, 277–287.

54. Giese,K., Kingsley,C., Kirshner,J.R. and Grosschedl,R. (1995) Assembly and function of a TCR alpha enhancer complex is dependent on LEP-1-induced DNA bending and multiple protein–protein interactions. *Genes Dev.*, 9, 995–1008.

55. Giese,K., Kingsley,C., Kirshner,J.R. and Grosschedl,R. (1995) Assembly and function of a TCR alpha enhancer complex is dependent on LEP-1-induced DNA bending and multiple protein–protein interactions. *Proc. Natl Acad. Sci. USA*, 92, 8180–8184.

56. Hansen,R.D., Grisolano,J.L. and Levy,T.J. (1993) Consensus AP-1 and CRE motifs upstream from the human cytoxic serum protease B (CSP-B/CGL-1) gene synergize to activate transcription. *Blood*, 82, 2749–2757.

57. Dunn,T.M., Hahn,S., Ogden,S. and Schleif,R.F. (1984) An operator at -280 base pairs that is required for repression of araBAD operon promoter: addition of DNA helical turns between the operator and promoter cyclically hinders repression. *Proc. Natl Acad. Sci. USA*, 81, 5017–5020.

58. Rao,E., Dang,W., Tian,G. and Sen,R. (1997) A three-protein-DNA complex on a B cell-specific domain of the immunoglobulin mu heavy chain gene enhancer. *J. Biol. Chem.*, 272, 6722–6732.

59. Ellwood,K., Huang,W., Johnson,R. and Carey,M. (1999) Multiple layers of cooperativity regulate enhanceosome-responsive RNA polymerase II transcription complex assembly. *Mol. Cell Biol.*, 19, 2613–2623.

60. Wang,J., Ellwood,K., Lehman,A., Carey,M.F. and She,Z.S. (1999) A mathematical model for synergistic eukaryotic gene activation. *J. Mol. Biol.*, 286, 315–325.

61. Hebner,C., Lasanen,J., Battle,S. and Aiyar,A. (2003) The spacing between adjacent binding sites in the family of repeats affects the functions of Epstein-Barr nuclear antigen 1 in transcription activation and stable plasmid maintenance. *Virology*, 311, 263–274.

62. Nikolajczyk,B.S., Nelsen,B. and Sen,R. (1996) Precision alignment of sites required for mu enhancer activation in B cells. *Mol. Cell Biol.*, 16, 4544–4554.

63. Xiong,G. and Maser,E. (2001) Regulation of the steroid-inducible 3alpha-hydroxysteroid dehydrogenase/carboxyl reductase gene in *Comamonas testosteroni*. *J. Biol. Chem.*, 276, 9961–9970.

64. Chi,T., Lieberman,P., Ellwood,K. and Carey,M. (1995) A general mechanism for transcriptional synergy by eukaryotic activators. *Nature*, 377, 254–257.

65. Lederer,H., Tovar,K., Baer,G., May,R.P., Hillen,W. and Heumann,H. (1989) The quaternary structure of Tet repressors bound to the Tn10-encoded tet gene control region determined by neutron solution scattering. *EMBO J.*, 8, 1257–1263.

66. Mitjak,D., Weber,C.C., Rimann,M. and Fussenegger,M. (2004) Design and in vivo characterization of self-inactivating human and non-human lentiviral expression vectors engineered for streptogramin-adjustable transgene expression. *Nucleic Acids Res.*, 32, e106.

67. Fussenegger,M., Moser,S., Mazur,X. and Bailey,J.E. (1997) Autoregulated multicistronic expression vectors provide one-step cloning of regulated product gene expression in mammalian cells. *Biotechnol. Prog.*, 13, 733–740.

68. Weber,W., Marty,R.R., Keller,B., Rimann,M., Kramer,B.P. and Fussenegger,M. (2002) Versatile macrolide-responsive mammalian expression vectors for multiregulated multigene metabolic engineering. *Biotechnol. Bioeng.*, 80, 691–705.